Biotech Daily

Thursday August 27, 2026

Daily news on ASX-listed biotechnology companies

*** ASX, BIOTECH DOWN: SYNTARA UP 8%; IMPEDIMED DOWN 17%**

*** INVICTUS: LIQUIDATOR APPOINTED, 'FUNDS COMING'**

*** MAYNE REVENUE DOWN 6% TO $384m; $88m LOSS TO $16m PROFIT**

*** MESOBLAST REVENUE UP 7-FOLD TO $167m; LOSS DOWN 44% TO $80m**

*** TRAJAN REVENUE DOWN 3% TO $161m; LOSS DOWN 86% TO $623k**

*** CLINUVEL REVENUE UP 1% TO $94m; PROFIT DOWN 6% TO $34m**

*** NOVA EYE REVENUE UP 19% TO $35m; LOSS DOWN 45% TO $5m**

*** BOTANIX REVENUE UP 487% TO $34m; LOSS DOWN 19% TO $70m**

*** IMPEDIMED REVENUE UP 15% TO $15m; LOSS UP 7% TO $25m**

*** CLARITY INTEREST REVENUE UP 68% TO $8m; LOSS UP 67% TO $107m**

*** DIMERIX REVENUE DOWN 22% TO $4m; LOSS UP 125% TO $30m**

*** PETER MAC: 'A.I. EQUALS HUMAN PATHOLOGIST FOR BREAST CANCER'**

*** MONASH UNI: 'ALANINE REVERSES FUNGI EFFECT ON IMMUNE SYSTEM'**

*** CLINUVEL 'CONSIDERS' NASDAQ LISTING, ASX DELISTING**

*** CONTROL BIONICS UNOTOUCH OMNI $13.4k US REIMBURSEMENT**

*** ENLITIC, IOWA RADIOLOGY $199k ENSIGHT DEAL**

*** STATE STREET REDUCES TO 9% OF COCHLEAR**

*** CITIGROUP TAKES 6.5% OF COCHLEAR**

*** PENGANA TAKES 6% OF IMUGENE**

*** OLGA SMEJKALOVA REPLACES CAMBIUM CO SEC MARK LICCIARDO**

MARKET REPORT

The Australian stock market fell 0.98 percent on Thursday August 27, 2026, with the ASX200 down 89.6 points to 9,038.2 points. Eleven of the Biotech Daily Top 40 companies were up, 22 fell, six traded unchanged and one was untraded.

Syntara was the best, up 0.2 cents or 8.0 percent to 2.7 cents, with 883,398 shares traded. Artrya and Neuren climbed more than four percent; Alcidion and Amplia were up more than three percent; Mesoblast, Polynovo, Racura and Saluda rose more than two percent; Prescient was up 1.5 percent; with Cochlear, CSL, Resmed and Telix up by less than one percent.

Yesterday's 0.1 cents or 20 percent best, Impedimed, led today's falls, down 0.1 cents or 16.7 percent to 0.5 cents, with 4.5 million shares traded. Clinuvel lost 12.7 percent; Paradigm fell 11.1 percent; Medical Developments shed 7.1 percent; Clarity, Optiscan and Proteomics were down more than six percent; EBR and Nanosonics lost more than five percent; 4D Medical, Actinogen, Botanix and Lumos fell more than four percent; Compumedics, Immutep, Nova Eye and Orthocell were down more than three percent; Pro Medicus shed 2.9 percent; Avita, Cyclopharm and Starpharma were down more than one percent; with Aroa and Imricor down by less than one percent.

INVICTUS THERAPEUTICS (FORMERLY VGI HEALTH TECHNOLOGY)

The Victoria Supreme Court has appointed liquidators to wind-up Invictus, with chief executive officer Dr Glenn Tong saying that funds are on the way.

Dr Tong told Biotech Daily that Invictus owed the Melbourne law firm Cornwalls about $55,000 including legal costs and had other outstanding amounts.

The matter was brought to the Supreme Court by Cornwalls, which appointed Alvarez & Marsal's Daniel Linaker and Glen Kanevsky as liquidators of Invictus.

Dr Tong told Biotech Daily that "we have commitments for some funds".

"There is more to come with this matter," Dr Tong said.

Last month, Invictus said it had been granted a US Patent for transmucosal tocotrienol for post-exercise and delayed onset muscle soreness (BD: Jul 30, 2026).

Dr Tong said that the transmucosal tocotrienol was currently in phase II trials for both pancreatic cancer and non-alcoholic steato-hepatitis (NASH).

Dr Tong said that a pro-drug version of tocotrienol was in pre-clinical studies with the Monash Institute of Pharmaceutical Sciences (MIPS) and was intended for pancreatic cancer and NASH.

In November 2025, the then VGI Health changed its name to Invictus (BD: Dec 5, 2025).

In January 2024, VGI said that it had had ethics approval for an 80-patient, placebo-controlled, phase II trial of its transmucosal tocotrienols, or IVB003, for pancreatic cancer in Australia (BD: Jan 21, 2024).

VGI said at that time that the trial would dose patients three times daily with 120mg of IVB003, with a primary endpoint of progression free survival.

In 2022, VGI said that subsidiary, Invictus Ops Pty Ltd, had begun its 80-patient, phase II trial of IVB001 for non-alcoholic fatty liver disease and non-alcoholic steato-hepatitis. VGI said at that time that the randomized, double-blind, placebo-controlled trial would analyze the efficacy and safety of IVB001 for non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steato-hepatitis (NASH) (BD: Sep 14,2022).

Invictus is listed on the National Stock Exchange (NSX), under the code VTL, last traded at 2.0 cents and is currently in liquidation.

MAYNE PHARMA

Mayne says revenue for the year to June 30, 2026 fell 6.0 percent to $383,676,000, with last year's $88,036,000 net loss after tax turned to a $16,077,000 profit.

Mayne said revenue was from sales of its women's health products including Bijuva, Nextsellis, Imvexxy and Annovera, down two percent to $174.3 million, with dermatology revenue down 10 percent to $138.7 million and revenue from product sales in non-US territories down seven percent to $70.7 million.

The company said its profit was "driven by a [non-cash] $125.6 million earn-out liability re-assessment gain".

Mayne chief executive officer Aaron Gray said "2025-'26 was a year in which we strengthened the foundations of the business and positioned the business for long term growth".

"While the Cosette transaction process and subsequent legal matters placed real demands on management focus and caused general disruption, we used the year to invest with conviction by increasing our women's health sales and promotional capability to capture the strong momentum we are seeing across the portfolio, particularly in menopause," Mr Gray said.

Earlier this year, the company said Cosette paid it $14,410,714 in accordance with orders made by the Supreme Court of New South Wales "in relation to Cosette's purported termination of the scheme implementation deed signed by Mayne and Cosette in February 2025" (BD: Feb 21, Nov 21, Dec 11, 2025; Jun 5, 2026).

Today, Mayne said it had diluted earnings per share of 21 cents compared to a $1.19 diluted loss per share in the prior corresponding period, with negative net tangible assets down 59.5 percent to negative 90 cents.

The company said it had cash and cash equivalents of $80,003,000 at June 30, 2026 compared to $59,839,000 at June 30, 2025.

Mayne fell five cents or 1.6 percent to $3.12.

MESOBLAST

Mesoblast says revenue for the year to June 30, 2026 was up 599.2 percent to $US120,250,000 ($A167,450,000), with net loss after tax down 43.7 percent to $US57,500,000 ($A80,069,000).

Mesoblast said revenue from product sales of its Ryoncil, or remestemcel-L, for steroid-refractory acute graft versus host disease was up 9.2-fold to $US115,153,000, with royalty revenue from Temcell sales in Japan down 14.1 percent.

Mesoblast chief executive Prof Silviu Itescu said the company was "very pleased to report a strong full year gross profit of $US104 million for 2025-'26".

"The financial result is a product of continued growth in Ryoncil market adoption and focus on disciplined capital allocation while investing in our high-value opportunities," Prof Itescu said.

"We plan to expand Ryoncil use to adults with severe steroid-refractory acute graft versus host disease as both a third-line treatment and as part of second-line treatment regimen together with ruxolitinib, a market three times larger than the pediatric market," Prof Itescu said.

The company said diluted loss per share fell 47.5 percent to 4.44 US cents, with net tangible asset backing per share down 92.6 percent to 0.25 US cents.

Mesoblast said it had cash and cash equivalents of $US102,914,000 at June 30, 2026 compared to $US161,551,000 at June 30, 2025.

Mesoblast was up five cents or 2.1 percent to $2.41 with 4.2 million shares traded.

TRAJAN GROUP

Trajan says revenue for the year to June 30, 2026 fell 3.05 percent to $161,377,000, with net loss after tax down 86.0 percent to $623,000.
Trajan said revenue was from its products and devices “used in the analysis of biological, food, and environmental samples” and was affected by “absorbing costs associated with establishing more localized ‘in-region, for-region’ manufacturing capability, elevated complexity from supply chain and tariff-related responses, restructuring actions and headcount reductions”.
Trajan said “cost reductions in headcount and facilities” resulted in a $1.2 million saving, with reduced corporate services headcount saving a further $1.2 million.
Trajan managing-director Stephen Tomisich said “2025-’26 was a year of two halves”.
“While the first quarter created a difficult starting point for the year, the business recovered operationally from [the three months to December 31, 2025] onward, and we delivered a materially stronger second half result,” Mr Tomisich said.
The company said diluted loss per share fell 86.2 percent to 0.4 cents, net tangible assets per share was unchanged at 12 cents; and it had cash and cash equivalents of $12,623,000 at June 30, 2026 compared to $11,851,000 at June 30, 2025.
Trajan fell 1.5 cents or 8.3 percent to 16.5 cents with 1.1 million shares traded.

CLINUVEL PHARMACEUTICALS

Clinuvel says revenue for the year to June 30, 2026 was up 1.0 percent to $94,024,398, with net profit after tax up 6.2 percent to $33,916,819.
Clinuvel said an increase in sales of Scenesse “in Europe offset marginal declines in US sales as some competitors offered free drug treatment to erythropoietic protoporphyria (EPP) patients”, with its expenses reduced.
The company said it was the tenth consecutive year of profit since the start of commercial distribution of Scenesse to treat EPP.
Clinuvel said it would pay a fully-franked dividend equal to the prior year of 5.0 cents a share on September 18, 2026 to investors on the record date of September 4.
The company said diluted earnings per share was up 2.9 percent to 71.8 cents, net tangible assets per share rose 12.2 percent to $5.35; and it had cash and equivalents of $252,055,000 at June 30, 2026 compared to $224,106,000 the prior year.
Clinuvel fell $1.34 or 12.7 percent to $9.18 with 768,363 shares traded.

NOVA EYE MEDICAL

Nova Eye says revenue for the year to June 30, 2026 was up 19.1 percent to $34,865,000, with net loss after tax down 44.5 percent to $4,786,000.
Nova Eye said that revenue was from sales of its Itrack and Itrack Advance glaucoma surgical devices as well as its Molteno3 device.
The company its gross margin improved due to increased sales in the US and Germany and lower manufacturing costs “driven by both scale and process improvements”.
Nova Eye said 2026-’27 sales, excluding China, was expected to be between $38 million to $45 million “implying growth of 15 percent to 37 percent on 2025-’26” and it expected positive Earnings before interest, taxation, depreciation and amortization.
The company said diluted loss per share fell 58.5 percent to 1.52 cents, with net tangible asset backing per share down 37.9 percent to 1.8 cents; and it had cash and cash equivalents of $964,000 at June 30, 2026 compared to $5,055,000 at June 30, 2025.
Nova Eye fell half a cent or 3.45 percent to 14 cents.

BOTANIX PHARMACEUTICALS

Botanix says revenue for the year to June 30, 2026 was up 487.1 percent to $33,801,507, with net loss after tax down 19.25 percent to $69,768,611.
Botanix said revenue was “primarily driven by the first full year of commercial sales of Sofdra [for excessive sweating] in the US, together with royalty revenue received from the company’s Japanese licencee and South Korean sub-licencee”.
The company said expenses increased as it invested in manufacturing inventory, expanded its commercial infrastructure, established the Botanix Fulfilment Platform, increased sales force and accelerated activities to support the launch and commercialization of Sofdra, partially offset by significant revenue growth.
Botanix said diluted loss per share fell 31.2 percent to 3.22 cents, with net tangible assets per share down 48.0 percent to 1.41 cents; and it had cash and equivalents of $36,631,217 at June 30, 2026 compared to $64,966,581 at June 30, 2025.
Botanix fell 0.1 cents or 4.8 percent to two cents with 12.05 million shares traded.

IMPEDIMED

Impedimed says revenue for the year to June 30, 2026 was up 14.8 percent to $14,613,000, with net loss after tax up 7.2 percent to $24,907,000.
Impedimed said revenue was from sales of its Sozo bioimpedance spectroscopy for lymphoedema, heart failure and medical weight management.
The company said the increased revenue was mainly due to new sales and recurring revenue growth in North America, with the loss driven by higher finance expense, partly offset by higher gross profit from new sales and recurring revenue growth, lower salaries, benefits and share-based payments expense, and lower depreciation and amortization”.
Impedimed said diluted loss per share was constant at 1.0 cent, with zero net tangible assets per share compared to 0.37 cents in the prior period; and it had cash and cash equivalents of $15,288,000 at June 30, 2026 compared to $22,183,000 the prior year.
Impedimed fell 0.1 cents or 16.7 percent to 0.5 cents with 4.5 million shares traded.

CLARITY PHARMACEUTICALS

Clarity says revenue from interest for the year to June 30, 2026 rose 68.1 percent to $8,003,686, with net lost after tax up 66.7 percent to $107,369,929.
Clarity said income related “to interest from bank and term deposits and is recognized on an accrual basis”, with $121,045,918 in term deposits, along with cash and equivalents of $57,207,778 at June 30, 2026 compared to $47,684,182 the prior year.
The company said diluted loss per share rose 44.8 percent to 29.1 cents, with net tangible assets per share up 77.6 percent to 49.9 cents.
Clarity fell 16 cents or 6.4 percent to $2.34 with 3.1 million shares traded.

DIMERIX

Dimerix says revenue for the year to June 30, 2026 fell 22.1 percent to $4,350,305, with net loss after tax up 125.0 percent to $29,813,353.
Dimerix said revenue related to income licence fees for its DMX-200 for focal segmental glomerulo-sclerosis (FSGS) with Everest Medicines.
Dimerix said diluted loss per share rose 110.6 percent to 4.97 cents, with cash and equivalents of $16,153,803 at June 30, 2026 compared to $68,283,812 at June 30, 2025.
Dimerix was unchanged at 29 cents with 1.1 million shares traded.

PETER MACCALLUM CANCER CENTRE

The Peter MacCallum Cancer Centre says that artificial intelligence (A.I.) models are “just as good as a human pathologist” at predicting breast cancer outcomes.
The Peter MacCallum said two studies showed that “A.I. models which count tumor-infiltrating lymphocytes in samples of breast tissue should be more widely used ‘particularly where routine or widespread pathologist assessment is unavailable’”.
The Peter MacCallum Centre said tumor-infiltrating lymphocytes were immune cells, which were counted by a pathologist in a microscope slide, with higher levels showing “a stronger immune response against the tumor”
The Centre said one study compiled results from seven clinical trials involving more than 1,300 patients with triple-negative breast cancer and found that “while A.I. and pathologist scores were not identical, both provided similar information about the patients’ prognosis”.
The Centre said the study, titled ‘Artificial intelligence-based tumour infiltrating lymphocyte quantification in patients with triple-negative breast cancer: an independent validation study’ was published in the Lancet Oncology, with a summary available at: https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(26)00339-6/abstract.
Peter MacCallum said the second study assessed more than 4,300 tumor samples from a phase III trial involving patients with early breast cancer and assessed tumor-infiltrating lymphocytes using pathologist scoring, digital image analysis and A.I.-based methods.
The Centre said that pathologist scoring, digital image analysis and A.I. all “showed patients with more [tumor-infiltrating lymphocytes] had better outcomes”.
Peter MacCallum said A.I. could “analyze how immune cells were organized and highlight ‘hotspots’ which provided additional prognostic information beyond simply counting [tumor-infiltrating lymphocytes]”.
The Centre said that the second study, titled ‘Manual, digital, and AI tumour-infiltrating lymphocyte scoring: a secondary analysis of the APHINITY randomised trial’ was published in the Lancet Oncology, with an abstract available at: https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(26)00247-0/abstract.
Peter MacCallum said the studies also strengthened the case for tumor-infiltrating lymphocytes “to be used as a practical biomarker in breast cancer, as well as showing that A.I. could enable their assessment at scale”.

MONASH UNIVERSITY

Monash University says the amino acid alanine reverses the processes the fungi Candida auris and Candida albicans use to defeat the immune system.
Monash University said that “when an immune cell ‘swallows’ a fungal microbe to destroy it, the fungus fights back from the inside, triggering the host protein Ninjurin (NINJ1) to form large pores, causing the immune cell to explode and release the fungal cells to spread the infection”.
The University said that “by supplying a higher dosage of alanine, researchers successfully blocked the protein, preventing the immune cells from bursting, thereby containing the fungal cells”.
Monash said the research provided “new avenues for treatments and drug discovery”.
The University said a first study, titled ‘Infection-induced glucose starvation triggers NINJ1-dependent macrophage lysis and Candida escape’ was published in Nature Communications at: https://www.nature.com/articles/s41467-026-74195-6.
Monash University said a second study, titled ‘Candida auris uses nutrient sensing to modulate virulence and host immune responses’ was published in Nature Microbiology at: https://www.nature.com/articles/s41564-026-02454-9.

CLINUVEL PHARMACEUTICALS

Clinuvel says it is “considering” listing on the Nasdaq and delisting from the ASX.
Clinuvel said its main research activities were undertaken in Singapore, while its commercial and clinical operations are managed from the UK, the European Union and the US; and it would open a US headquarters, effective from January 1, 2027.
The company said the proposed Nasdaq listing reflected the increasing significance of its current and future operations in the US, “the largest global market in scientific innovation”.
Clinuvel said the transaction would be implemented by way of a scheme of arrangement and would be subject to shareholder and court approval.
The company said under the transaction, a foreign holding company would become the parent company of the Clinuvel Group and that current shareholders would receive ordinary shares in the holding company representing an equivalent proportionate economic interest to their existing interest.
Clinuvel said a final board decision had “not yet been made to proceed with the transaction and due diligence continues with input from global counsel and auditors”.
Clinuvel managing-director Dr Philippe Wolgen said the company had “methodically and gradually worked towards the moment whereby the company has reached maturity of its operations, [research and development] capabilities and balance sheet to support consideration of gaining access to a larger life sciences capital market”.
Dr Wolgen said all the company’s revenues were “generated in Europe and North America, our future pharmaceutical activities target … North America, and the majority of our senior executives [are] based outside Australia”.
“We believe it is thus appropriate to consider whether a US-focused group and Nasdaq listing better align with the company’s future operations and strategic direction,” Dr Wolgen said.

CONTROL BIONICS

Control Bionics says it has a US Medicare billing code covering its Unotouch Omni speech generating device at up-to $US9,646 ($A13,432) per device in the US.
Control Bionics said it had a Healthcare Common Procedure Coding System (HCPCS) coding verification from the Pricing, Data Analysis and Coding (PDAC) contractor for its Unotouch Omni speech generating devices.
Earlier this year, the company said with Nextlevel Assistive Technology it would commercialize a range of Apple Iphone operating system (IOS)-based speech generating devices in the US (BD: Feb 26, 2026).
Today, Control Bionics said the code allowed the Unotouch Omni range to be funded through the US reimbursement system, clearing the way for US sales to commence.
The company said that verification “was the final pre-requisite” for US sales of the Unotouch Omni range, with claims to be billed to all four durable medical equipment Medicare Administrative Contractors.
Control Bionics managing-director Jeremy Steele said coding verification was “the gate every speech generating device must pass before it can be funded in the US”.
“Our distribution partners can bill these devices through the workflows they already run every day,” Mr Steele said.
“More Americans who cannot speak will have access to a proven device that helps give them a voice,” Mr Steele said.
“With coding now resolved, our focus is on supporting our launch customer’s rollout plans, with first revenue targeted for September,” Mr Steele said.
Control Bionics fell 0.1 cents or 1.6 percent to six cents with 5.5 million shares traded.

ENLITIC

Enlitic says it has a $US143,000 ($A199,000) contract with Cedar Rapids' Radiology Consultants of Iowa for its Ensight medical imaging data management platform.
Enlitic said the agreement was its second US customer deployment through its integration with Intelerad and added $US40,000 in annual recurring revenue.
The company said revenue from the initial deployment reflected "limited scope of Ensight's broader functionality and does not represent a full-platform rollout".
Enlitic said Ensight was "designed as a modular platform with additional functionality that can be added progressively as customer requirements develop".
Enlitic managing-director Michael Sistenich said that "once embedded and in regular use, there is a significant opportunity to deploy additional Ensight modules, workflows and sites".
"We expect [annual recurring revenue] to build rapidly under our 'land-and-expand' strategy as new and existing customers broaden their use of Ensight," Mr Sistenich said.
"These two recent contract wins provide further validation of our [software-as-a-service] mode, the value Ensight can deliver to Intelerad customers and our continued expansion across the global medical imaging market," Mr Sistenich said.
"With a strong pipeline across these markets, we expect our dependable and predictable revenue base to continue growing strongly," Mr Sistenich said.
Enlitic was untraded at 0.5 cents.

COCHLEAR

Boston's State Street Corporation says it has reduced its substantial shareholding in Cochlear from 6,756,114 shares (10.33%) to 6,095,584 shares (9.32%).
State Street said between August 13 and 24, 2026 it bought, sold, lent and received shares, with the sales at prices ranging from $133.93 a share to $142.00 a share.
Cochlear was up five cents or 0.04 percent to $137.76 with 510,135 shares traded.

COCHLEAR

Citigroup Global Markets Australia says it has increased its substantial shareholding in Cochlear from 3,463,170 shares (5.2955%) to 4,284,690 shares (6.5516%).
Sydney's Citigroup said its holding increased due to "contracts entered into in the ordinary course of business" and an "obligations to return [shares] under securities lending agreements".

IMUGENE

Pengana Capital Group says it has become a substantial shareholder in Imugene with 31,540,076 shares, or 6.44 percent of the company.
Sydney's Pengana said that on August 20, 2026 it acquired 26,315,790 shares in a placement for $2,500,000, or 9.5 cents a share.
Last month, Imugene said it had "firm commitments" to raise about $11.12 million in a placement at 9.5 cents a share (BD: Jul 7, 2026).
Imugene was unchanged at 7.1 cents with 3.5 million shares traded.

CAMBIUM BIO

Cambium says Mark Licciardo has resigned as company secretary, effective from August 27, 2026, with Acclime Australia's Olga Smejkalova appointed as replacement.
Cambium said Ms Smejkalova was an experienced governance professional with corporate governance, regulatory compliance and company secretarial experience.
Cambium was untraded at 42 cents.